83% of pharma's trials published

More than eight out of 10 pharma-sponsored clinical trials made it into a peer-reviewed journal, a 23% increase over the 2008 rate, researchers showed.

Executives interviewed think the hike is likely driven by more stringent demands for investigators to publish, said research firm Cutting Edge Information.

Drug companies are holding investigators more accountable for publishing to journals, the firm said. Many write publication clauses in contracts, making final milestone payments conditional on publication of trial results.

One drug company no longer accepts proposals from investigators unwilling to agree to write trial data up for publication, Cutting Edge said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.